Search

IJMSC: Investigating the Impact of Polypharmacy and Anticholinergic Medication Burden on Objective Performance in Adults With Multiple Sclerosis

Release Date: March 1, 2024 Valid for Credit through: March 1, 2025 Activity Available Online: To access the article and evaluation online, go to https://www.highmarksce.com/mscare. Target Audience: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, pharmacists, researchers, and other health care providers involved in the study and management of patients …

A Clinician’s Guide to the 2021 MAGNIMS-CMSC-NAIMS Consensus Recommendations on the use of MRI in Patients with MS

Released On: December 31, 2023 Expires On: December 31, 2024 This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC)and Catamount Medical Education. This activity is supported by an independent educational grant from Genentech, A Member of the Roche Group. Target Audience This activity is intended for neurologists, radiologists, primary care clinicians, …

Updates in Cognition and Multiple Sclerosis: Expert Guidance on Management Across the Continuum of the Disease

1.5 Continuing Education Credits available for Physicians, Nurses, Pharmacists, and Psychologists RELEASE DATE: September 29, 2023 EXPIRATION DATE: September 29, 2024 The estimated time to complete the activity is 90 minutes. This activity is supported by an independent educational grant from Bristol Myers Squibb. This activity is jointly provided by The Consortium of Multiple Sclerosis …

Neuromyelitis Optica Spectrum Disorder: Updates on Diagnosis and Treatment Management

Valid: July 7, 2023 through July 6, 2024 Provider Statement This continuing education activity is provided by  Support Statement This activity is supported by an educational grant from Horizon Therapeutics USA, Inc. Activity Description Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that is characterized by inflammation …

ForuMS: Highlights in MS Care from 2022

Released On: May 15, 2023 Expires On: May 15, 2024 Provider Statement This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. Support Statement This activity is supported by independent educational grants from Novartis Pharmaceuticals Corporation Credit Available Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™ Nurses — 1.25 …

PatientGPS™: Clinical Paths in ModernTreatment of Multiple Sclerosis

Released: April 5, 2023 Expires: April 5, 2024 Program Description An interactive and patient-centric CE learning experience, including discussion of patient cases depicting clinical challenges associated with the personalized treatment of multiple sclerosis (MS). Intended Audience Neurologists, advanced practice clinicians, nurses, pharmacists, and other clinicians who are part of the team that manages patients with …

Contemporary Considerations in Multiple Sclerosis Treatment: A Post-Pandemic Educational Curriculum MedPoints™ in Multiple Sclerosis

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. This activity is supported by independent educational grants fromBiogen and Bristol Myers Squibb. Target Audience MS specialists, general neurologists, nursing professionals, pharmacists, PAs, and patient advocates in the care of people living with multiple sclerosis (MS). Faculty Robert …

Building Clinical Confidence: Evidence-based Care for People Living with MS

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC)and Catamount Medical Education. This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC and Sanofi. Target Audience Neurologists, primary care physicians, nurse practitioners, nurses, physician associates (PAs), rehabilitation specialists, mental health specialists, radiologists, and other clinicians who are part …

Collaborating Across the Continuum™: Managing Relapsing MS – A Focus on the Utility of CD20-Targeted B-Cell Therapy

Release Date: November 30, 2022 Expiration Date: November 30, 2023 Faculty: Stephen Krieger, MD, FAAN Jacci Bainbridge, PharmD, FCCP Denise Bruen, ANP-BC, MSN, MSCN Activity Overview Following the success of anti-CD20 antibodies in the treatment of multiple sclerosis (MS), there has been a shift in understanding of its pathophysiology. B cells have been identified as …